Thrombotic microangiopathy associated with gemcitabine: rare but real.

abstract：INTRODUCTION:Traditional Chinese medicine (TCM) is widely used around the world. However, with its wide use has been the identification of a number of toxicological issues that have severely restricted its use in clinical treatment. The identification of these toxic substances within TCM has become somewhat of a hot to...

journal_title：Expert opinion on drug safety

authors： Lv W,Piao JH,Jiang JG

更新日期：2012-11-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Bisphosphonates are the most widely used antiresorptive agents for the treatment of osteoporosis. However, the cumulative bisphoshonate exposure and its association with atypical fragility fractures, and the optimum duration of treatment remain obscure. AREAS COVERED IN THIS REVIEW:This review ...

journal_title：Expert opinion on drug safety

authors： Charopoulos I,Orme S,Giannoudis PV

更新日期：2011-01-01 00:00:00

abstract：:Psychosis in Alzheimer's disease is common and troublesome. The impact on the quality of life of both patients and caregivers is high and drug treatments raise concern in terms of both efficacy and safety. Therefore, identifying the risk factors that play an important role in the onset of psychosis is mandatory for th...

journal_title：Expert opinion on drug safety

authors： Cancelli I,Beltrame M,D'Anna L,Gigli GL,Valente M

更新日期：2009-09-01 00:00:00

abstract：:It is estimated that over three-quarters of a million people are injured or die in hospitals each year from adverse drug events (ADEs). The majority of medical errors result from poorly designed healthcare systems rather than from negligence on the part of healthcare providers. In general, healthcare systems rely on v...

journal_title：Expert opinion on drug safety

authors： Anderson JG

更新日期：2004-09-01 00:00:00

abstract：:This meeting was convened to encourage the incorporation of empirical and mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) modelling into safety pharmacology to improve the predictability of nonclinical investigations for human outcomes. These technologies make use of mathematical expressions relating measured ...

journal_title：Expert opinion on drug safety

authors： Cavero I

更新日期：2007-07-01 00:00:00

abstract：:The optimum anti-HIV drug has yet to be found. This paper will summarise some of the oral adverse effects associated with antiretroviral agents against HIV. The development of antiretroviral drugs for the treatment of HIV infection has been aimed at the inactivation of two HIV enzymes: reverse transcriptase and protea...

journal_title：Expert opinion on drug safety

authors： Diz Dios P,Scully C

更新日期：2002-11-01 00:00:00

abstract：INTRODUCTION:In the past two decades, the number of women with autoimmune and inflammatory diseases experiencing a pregnancy has significantly increased in parallel with the enormous advances in the diagnosis and management of these disorders. However, information regarding the safety of immunosuppressive agents comes ...

journal_title：Expert opinion on drug safety

authors： Gerosa M,Meroni PL,Cimaz R

更新日期：2014-12-01 00:00:00

abstract：INTRODUCTION:Reslizumab, a humanized mAb against IL-5, reduces the number of eosinophils in the blood and lungs. Based on efficacy and safety data from pivotal RCTs, reslizumab had been approved for use as an add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults who have a history of ex...

journal_title：Expert opinion on drug safety

authors： Cazzola M,Matera MG,Levi-Schaffer F,Rogliani P

更新日期：2018-04-01 00:00:00

abstract：INTRODUCTION:During the last decade, the development of small molecule inhibitors of Janus kinases (JAKi) contributed to revolutionize the therapeutic landscape of myelofibrosis (MF). JAKi proved to be effective in controlling disease-related symptoms and splenomegaly with remarkable inter-drug variability. However, in...

journal_title：Expert opinion on drug safety

authors： Coltro G,Vannucchi AM

更新日期：2020-12-27 00:00:00

abstract：INTRODUCTION:The goal of antiviral therapy in patients with chronic hepatitis C is to slow or halt the progression of fibrosis and prevent the development of cirrhosis. Accordingly, antiviral treatment is proposed for a large population of patients with chronic hepatitis. AREAS COVERED:The standard-of-care for chronic...

journal_title：Expert opinion on drug safety

authors： Calvaruso V,Mazza M,Almasio PL

更新日期：2011-05-01 00:00:00

abstract：INTRODUCTION:Mood stabilizer (MS) plus antipsychotic (AP) co-treatment is common in patients with acute bipolar disorder (BD), but adverse effects (AEs) of this strategy have not been systematically reviewed. AREAS COVERED:We conducted a systematic review searching PubMed/MEDLINE and PsycINFO on April 1, 2015 for rand...

journal_title：Expert opinion on drug safety

authors： Galling B,Garcia MA,Osuchukwu U,Hagi K,Correll CU

更新日期：2015-08-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Trastuzumab has become a mainstay in the treatment of women with human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer in the metastatic and adjuvant settings. Although trastuzumab is generally well tolerated, cardiac toxicity has emerged as a rare but potentially serious ...

journal_title：Expert opinion on drug safety

authors： Chien AJ,Rugo HS

更新日期：2010-03-01 00:00:00

abstract：INTRODUCTION:Secukinumab is a human monoclonal antibody that selectively targets and neutralizes interleukin (IL)-17A, a cytokine that is normally involved in mucocutaneous defense against extracellular organisms and is abnormally expressed in psoriasis. In 2015, secukinumab was the first IL-17A inhibitor approved for ...

journal_title：Expert opinion on drug safety

authors： Blauvelt A

更新日期：2016-10-01 00:00:00

abstract：OBJECTIVE:To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association. METHODS:The open-label study ETV-901 (AI463901) assessed the safety of entecavir in chronic hepatitis B patients who received entecavir, lamivudine or adefovir monothe...

journal_title：Expert opinion on drug safety

authors： Manns MP,Akarca US,Chang TT,Sievert W,Yoon SK,Tsai N,Min A,Pangerl A,Beebe S,Yu M,Wongcharatrawee S

更新日期：2012-05-01 00:00:00

abstract：INTRODUCTION:Cardiovascular (CV) diseases are the leading cause of death and disability in the developed countries. Lipid-lowering therapy is a cornerstone of the CV risk modification strategy. The first line treatment for hyperlipidemia is statins, which decrease low-density lipoprotein cholesterol (LDL-C) by 30-50% a...

journal_title：Expert opinion on drug safety

authors： Strilchuk L,Fogacci F,Cicero AF

更新日期：2019-07-01 00:00:00

abstract：INTRODUCTION:A growing number of children globally are being treated for multidrug-resistant tuberculosis (MDR-TB). The second-line injectable antituberculosis medications amikacin, kanamycin and capreomycin, traditionally a mainstay of MDR-TB treatment, cause important adverse effects including permanent sensorineural...

journal_title：Expert opinion on drug safety

authors： Garcia-Prats AJ,Schaaf HS,Hesseling AC

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:Maraviroc is the only C-chemokine receptor 5 (CCR5) antagonist approved for the treatment of infection with HIV. This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection. AREAS COVERED:The PubMed database was searched using the keywords 'maraviroc' and 'HIV'. In addition...

journal_title：Expert opinion on drug safety

authors： Wasmuth JC,Rockstroh JK,Hardy WD

更新日期：2012-01-01 00:00:00

abstract：INTRODUCTION:Pomalidomide, a derivative of thalidomide and member of the immunomodulatory drugs is licenced for use in relapsed and refractory multiple myeloma (RRMM) in Europe, USA, Canada and Japan. AREAS COVERED:This review details all published trials in which pomalidomide has been used in the treatment of myeloma...

journal_title：Expert opinion on drug safety

authors： Jones JR,Pawlyn C,Davies FE,Morgan GJ

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Niacin is one of the oldest drugs used in the treatment of dyslipidemia. Previously its use has been limited because of excessive flushing. Now an agent laropiprant (LRP) has been developed, which blocks the flushing pathway. Therefore, it is time to collate available information to assess the safety and t...

journal_title：Expert opinion on drug safety

authors： Yadav R,Kwok S,Ammori BJ,Issa B,Soran H

更新日期：2012-01-01 00:00:00

abstract：:Aerosolized delivery of a number of antimicrobial agents has been studied. Despite a theoretical soundness behind this strategy, full consideration of the potential toxicities associated with this mode of administration is imperative. Aerosolized amphotericin B, as both deoxycholate and lipid formulations, has been st...

journal_title：Expert opinion on drug safety

authors： Knechtel SA,Klepser ME

更新日期：2007-09-01 00:00:00

abstract：:The aim of this manuscript is to report the safety profile of patients treated with ruboxistaurin mesylate (RBX; LY333531), a selective protein kinase C-beta (PKC-beta) inhibitor, for up to 4 years. Data from patients with diabetes (1396 RBX 32 mg/day; 1408 placebo) were combined from 11 placebo-controlled, double-mas...

journal_title：Expert opinion on drug safety

authors： McGill JB,King GL,Berg PH,Price KL,Kles KA,Bastyr EJ,Hyslop DL

更新日期：2006-11-01 00:00:00

abstract：INTRODUCTION:Carbonic anhydrase (CA) inhibitors have an impressive safety record despite the multiple functions that CA isozymes serve because they are not fully inhibited with most dosing. While reducing the targeted CA-dependent process sufficiently for disease control, residual activity and uncatalyzed rates in comb...

journal_title：Expert opinion on drug safety

authors： Swenson ER

更新日期：2014-04-01 00:00:00

abstract：:Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states' varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relativ...

journal_title：Expert opinion on drug safety

authors： Afifi S,Mohamed S,Zhao J,Foss F

更新日期：2019-09-01 00:00:00

abstract：:Introduction: Patients living with schizophrenia have a marked risk of clinically significant weight gain and obesity compared to the general population. The risks have been highlighted following the introduction of second-generation antipsychotics. In turn, obesity is associated with a higher prevalence of cardiovasc...

journal_title：Expert opinion on drug safety

authors： Marteene W,Winckel K,Hollingworth S,Kisely S,Gallagher E,Hahn M,Ebdrup BH,Firth J,Siskind D

更新日期：2019-12-01 00:00:00

abstract：:Self-medication, using non-prescription drugs, is beneficial to patients, healthcare professionals, the pharmaceutical industry and governments. Although many non-prescription medications are effective, misuse and abuse of these products can arise. Monitoring of specific populations and products, in addition to data r...

journal_title：Expert opinion on drug safety

authors： Hughes CM

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. OBJECTIVES:To ascer...

journal_title：Expert opinion on drug safety

authors： Singh S,Loke YK

更新日期：2008-09-01 00:00:00

abstract：:Black cohosh (Actaea racemosa/Cimicifuga racemosa) is a North American perennial plant that has been used for traditional medicinal purposes by the native Indian population. Its modern day application is the treatment of menopausal symptoms. Unlike conventional non-herbal medications, herbal preparations have not been...

journal_title：Expert opinion on drug safety

authors： Huntley A

更新日期：2004-11-01 00:00:00

abstract：:NSAIDs are used extensively worldwide at a cost of billions of dollars annu-ally. Adverse side effects, especially in the gastrointestinal (GI) tract, are uncommon but cause a substantial burden of illness because of the volume of use. Important upper GI complications include dyspepsia, gastric erosions and peptic ulc...

journal_title：Expert opinion on drug safety

authors： Peng S,Duggan A

更新日期：2005-03-01 00:00:00

abstract：INTRODUCTION:Development of new drugs in oncology may have implications for cardiovascular risk. This report describes some aspects of our growing knowledge in the area of evaluating benefit-risk and may be of direct importance to scientists working in drug discovery and development. AREAS COVERED:This report of webin...

journal_title：Expert opinion on drug safety

authors： Braddock M,Heilbraun J,Mendzelevski B

更新日期：2013-09-01 00:00:00

abstract：INTRODUCTION:The antimalarial drug hydroxychloroquine (HCQ) is widely used to treat various rheumatic diseases. Many autoimmune diseases occur in women of child-bearing age who may become pregnant while on therapy, which raises concerns regarding the teratogenicity of HCQ and its effect on the outcome of the pregnancy....

journal_title：Expert opinion on drug safety

authors： Abarientos C,Sperber K,Shapiro DL,Aronow WS,Chao CP,Ash JY

更新日期：2011-09-01 00:00:00